Insights derived from analysing SEC filings. Independent analysis, not a publication of the SEC.
Figures are read from the Forms 10-K for FY2022, FY2023, FY2024 and FY2025, the Forms 10-Q for Q1 to Q3 2026 (Q3 2026 10-Q filed on 9 Nov 2026), the Forms 8-K with all their exhibits, incl. the quarterly earnings releases (Ex 99.1) and the shareholder letters (Ex 99.2) for Q4 2024 and Q4 2025, which carry the CFO commentary and guidance (Hims & Hers files no separate CFO commentary document and moved to an annual shareholder letter in 2026), the Form 8-K of 9 Nov 2026 on the board appointment, the Forms 8-K on the change of principal accounting officer, the 2026 proxy statement, the Form 8-K Item 5.07 vote results of the annual meeting and Forms 4, together with the filings of Teladoc, LifeMD, GoodRx, WW International, Novo Nordisk (Form 6-K) and Eli Lilly used in chapters 2 to 4 and 8. Accession numbers for every filing used appear in the Sources appendix. Share price $19.13 is the close of 10 Nov 2026.
| Line | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|
| Revenue ($m) | 599.0 | 617.8 | 608.1 | 753.2 | 890.4 |
| Revenue growth year on year (%) | n/a | n/a | 3.8 | 38.3 | 48.6 |
| United States revenue ($m) | 543.5 | 554.1 | 529.9 | 621.8 | 657.1 |
| Rest of the World revenue ($m) | 55.5 | 63.7 | 78.2 | 131.4 | 233.3 |
| Rest of the World share of revenue (%) | 9.3 | 10.3 | 12.9 | 17.4 | 26.2 |
| Gross margin (%) | 73.8 | 71.9 | 65.3 | 63.8 | 57.2 |
| Subscribers, end of quarter (thousands) | 2,471 | 2,511 | 2,584 | 2,891 | 2,788 |
| Net subscriber additions (thousands) | 32 | 40 | 73 | 307 | (103) |
| Monthly revenue per average subscriber ($) | 81 | 83 | 80 | 92 | 105 |
| Adjusted EBITDA, non GAAP ($m) | 78.4 | 66.3 | 44.3 | 60.3 | 82.4 |
| Net income (loss) ($m) | 15.8 | 20.6 | (92.1) | (86.3) | (33.0) |
| Period | Disclosure | Source |
|---|---|---|
| FY2024 | Revenue excluding the GLP‑1 offering $1.2bn against almost $1.5bn in total (rounded as filed) | 8-K Ex 99.2, Q4 2024 letter |
| FY2025 outlook | At least $725m from weight loss offerings (oral, liraglutide, personalized semaglutide); no FY2025 actual filed | 8-K Ex 99.2, Q4 2024 letter |
| FY2025 | Weight Loss, Men's Dermatology, Sexual Health and Women's Dermatology each above $100m of annual revenue; Hers brand approaching $1bn; Hims revenue up more than 30%, Hers more than 100% | 8-K Ex 99.2, Q4 2025 letter |
| FY2025 and Q1 to Q3 2026 | A majority of FY2025 revenue and of US revenue in each 2026 quarter came from offerings other than GLP‑1 | Q4 2025 letter; 10-Q MD&A |
| Q1 2025 to Q3 2026 | Hers share of US revenue about 40%, 35%, 40% (Q1 to Q3 2025), about 40% (Q1 2026), over 40% (Q2 2026) and about 45% (Q3 2026) | 10-Q MD&A |
| Q3 2026 | Eucalyptus about 15% of revenue (about 10% of 9M 2026 revenue); Zava not reported separately | 10-Q Q3 2026, Note 3 |
| Company | Line | Period | Detail | Revenue | Growth (%) | Op. margin (%) |
|---|---|---|---|---|---|---|
| Hims & Hers | US revenue (no weight loss line filed) | Q3 2026 | gross margin 57%; branded GLP‑1 since Mar 2026 | $657.1m | 20.9 | (8.1) |
| Eli Lilly | Zepbound revenue | Q3 2026 | Mounjaro $10.72bn (+64.6%); Mounjaro, Zepbound and Foundayo 66.6% of revenue | $5.35bn | 49.2 | 40.3 |
| Novo Nordisk | Wegovy pill sales | Q3 2026 | Wegovy injectable DKK 20.41bn (2% lower, CER); obesity care DKK 26.15bn, +22% | DKK 5.39bn | n/a | 29.1 |
| WW International | Revenue | Q3 2026 | net income $15.1m; long term debt $424.0m | $152.9m | (11.2) | 23.9 |
| LifeMD | Revenue (as filed, under correction) | Q2 2026 | NT 10-Q of 9 Nov 2026 cites revenue over recognized 2024 to Q2 2026 | $47.3m | (3.5) | (15.1) |
| GoodRx | Pharma Direct revenue (preliminary restated) | Q2 2026 | restated from $61.6m (8-K Item 4.02) | $83.9m | n/a | 17.3 |
| Company | Line | Period | Detail | Revenue | Growth (%) | Op. margin (%) |
|---|---|---|---|---|---|---|
| Hims & Hers | Revenue | Q3 2026 | subscribers 2.788m; $105 per subscriber a month | $890.4m | 48.6 | (7.4) |
| Teladoc Health | Revenue | Q3 2026 | BetterHelp $206.6m (12.8% lower); Integrated Care $398.5m (+2.3%) | $605.1m | (3.4) | (4.6) |
| GoodRx | Revenue (preliminary restated) | Q2 2026 | as reported $200.4m (1.3% lower) | $222.7m | 9.7 | 17.3 |
| LifeMD | Revenue (as filed, under correction) | Q2 2026 | gross margin 88.8% | $47.3m | (3.5) | (15.1) |
| WW International | Revenue | Q3 2026 | gross margin 71.1% | $152.9m | (11.2) | 23.9 |
| Company | Line | Period | Detail | Revenue | Growth (%) | Op. margin (%) |
|---|---|---|---|---|---|---|
| Hims & Hers | Rest of the World revenue | Q3 2026 | 26.2% of revenue; Eucalyptus about 15% of revenue | $233.3m | +321 (filed) | n/a |
| Novo Nordisk | International Operations sales | Q3 2026 | constant exchange rates; EUCAN DKK 19.86bn (+18%) | DKK 37.32bn | 8.0 | n/a |
| Teladoc Health | Non US revenue | Q3 2026 | 19% of revenue | $115.9m | (0.7) | n/a |
| Eli Lilly | Foundayo (orforglipron) revenue | Q3 2026 | oral GLP‑1; $98m in Q2 2026 | $184.0m | n/a | n/a |
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM Q3 2026 |
|---|---|---|---|---|---|---|
| Revenue | 0.3 | 0.5 | 0.9 | 1.5 | 2.3 | 2.9 |
| Gross profit | 0.2 | 0.4 | 0.7 | 1.2 | 1.7 | 1.8 |
| Research and development | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | n/a |
| Selling, general and administrative | 0.2 | 0.4 | 0.6 | 0.8 | 1.2 | n/a |
| Operating income | (0.1) | (0.1) | 0.0 | 0.1 | 0.1 | (0.2) |
| Net income | (0.1) | (0.1) | 0.0 | 0.1 | 0.1 | (0.2) |
| Diluted EPS ($) | (0.58) | (0.32) | (0.11) | 0.53 | 0.51 | n/a |
| Operating cash flow | 0.0 | 0.0 | 0.1 | 0.3 | 0.3 | 0.2 |
| Capital expenditure | 0.0 | 0.0 | 0.0 | (0.1) | (0.2) | (0.2) |
| Free cash flow | 0.0 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 |
| Stock based compensation | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.2 |
| Cash and investments | 0.2 | 0.2 | 0.2 | 0.3 | 0.9 | 0.7 |
| Total debt | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 1.4 |
| Total equity | 0.3 | 0.3 | 0.3 | 0.5 | 0.5 | 0.4 |
| Metric | Q3 2025 | Q3 2026 | Change |
|---|---|---|---|
| Revenue ($bn) | 0.60 | 0.89 | 48.6% |
| Gross profit ($bn) | 0.44 | 0.51 | 15.2% |
| Operating income ($bn) | 0.01 | (0.07) | n/a |
| Net income ($bn) | 0.02 | (0.03) | n/a |
| Diluted EPS ($) | 0.06 | (0.14) | n/a |
| Operating cash flow ($bn) | 0.15 | 0.07 | (56.0%) |
| Free cash flow ($bn) | 0.08 | 0.03 | (67.3%) |
| Operating margin (%) | 2.0 | (7.4) | (9.4 pts) |
| Net margin (%) | 2.6 | (3.7) | (6.3 pts) |
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM Q3 2026 |
|---|---|---|---|---|---|---|
| Growth and margins | ||||||
| Revenue growth (%) | n/a | 93.8 | 65.5 | 69.3 | 59.0 | n/a |
| Gross margin (%) | 75.2 | 77.6 | 82.0 | 79.5 | 73.8 | 63.8 |
| Operating margin (%) | (42.3) | (13.0) | (3.4) | 4.2 | 4.5 | (8.1) |
| Net margin (%) | (39.6) | (12.5) | (2.7) | 8.5 | 5.5 | (6.6) |
| FCF margin (%) | (14.5) | (6.4) | 5.4 | 13.4 | 2.4 | 0.3 |
| Cost and investment intensity | ||||||
| SBC (%) revenue | 24.7 | 8.1 | 7.6 | 6.3 | 5.8 | 6.2 |
| Capex (%) revenue | 1.8 | 1.4 | 3.0 | 3.6 | 10.3 | 6.0 |
| Returns | ||||||
| ROE (%) | (32.2) | (20.3) | (7.2) | 30.7 | 25.2 | (53.7) |
| ROA (%) | (25.6) | (16.7) | (5.8) | 21.9 | 9.0 | (5.4) |
| Asset turnover (x) | 0.65 | 1.44 | 1.98 | 2.09 | 1.09 | 0.81 |
| Liquidity and leverage | ||||||
| Current ratio (x) | 3.41 | 4.52 | 3.00 | 1.79 | 1.90 | 0.92 |
| Debt to equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 1.80 | 3.85 |
| Net cash ($bn) | 0.2 | 0.2 | 0.2 | 0.3 | 0.0 | (0.7) |
| Efficiency and cash quality | ||||||
| Days sales outstanding | n/a | n/a | n/a | n/a | 5 | 54 |
| Inventory days | 74 | 67 | 52 | 77 | 48 | 38 |
| FCF to net income (x) | n/a | n/a | n/a | 1.57 | 0.45 | n/a |
| Measure | Value |
|---|---|
| Market cap ($bn) | 4.5 |
| Enterprise value ($bn) | 5.1 |
| EV/Sales (TTM) (x) | 1.8 |
| FCF yield (%) | 0.2 |
| Price/Book (x) | 12.6 |
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM Q3 2026 |
|---|---|---|---|---|---|---|
| Revenue | 271.9 | 526.9 | 872.0 | 1,476.5 | 2,347.6 | 2,869.5 |
| Gross profit | 204.5 | 408.7 | 714.9 | 1,173.1 | 1,733.4 | 1,831.2 |
| Operating income (loss) | (115.0) | (68.7) | (29.5) | 61.9 | 105.6 | (232.5) |
| Net income (loss) | (107.7) | (65.7) | (23.5) | 126.0 | 128.4 | (190.8) |
| Adjusted EBITDA, non GAAP | n/a | n/a | n/a | 176.9 | 318.0 | 253.3 |
| Operating cash flow | (34.4) | (26.5) | 73.5 | 251.1 | 300.0 | 180.1 |
| Capital expenditure, company definition | 5.0 | 7.2 | 26.5 | 52.8 | 242.6 | 171.9 |
| Free cash flow | (39.4) | (33.8) | 47.0 | 198.3 | 57.4 | 8.2 |
| Stock based compensation | 67.2 | 42.8 | 66.1 | 92.3 | 135.2 | 177.9 |
| Share repurchases | 0.0 | 0.0 | 2.0 | 83.0 | 90.0 | 80.5 |
| Cash and investments | 247.3 | 179.6 | 221.0 | 300.3 | 928.8 | 712.2 |
| Total debt, carrying value | 0.0 | 0.0 | 0.0 | 0.0 | 972.6 | 1,367.4 |
| Total equity | 334.6 | 311.7 | 344.0 | 476.7 | 540.9 | 355.3 |
| Item | Outlook | Source |
|---|---|---|
| FY2026, set 23 Feb 2026 | revenue $2.7bn to $2.9bn; adjusted EBITDA $300m to $375m (11% to 13% margin); excludes Eucalyptus; assumes continued access to compounded semaglutide | 8-K Ex 99.1 |
| FY2026, set 11 May 2026 | revenue $2.8bn to $3.0bn; adjusted EBITDA $275m to $350m (10% to 12% margin); excludes Eucalyptus; after March 2026 shift to branded GLP‑1 | 8-K Ex 99.1 |
| FY2026, set 10 Aug 2026 | revenue $3.1bn to $3.3bn; adjusted EBITDA $275m to $325m (9% to 10% margin); first outlook after the Eucalyptus closing on 1 Jun 2026 | 8-K Ex 99.1 |
| FY2026, set 9 Nov 2026 | revenue $3.13bn to $3.15bn; adjusted EBITDA $257m to $277m (8% to 9% margin); midpoint revenue $3.14bn; midpoint EBITDA cut by $33m vs August | 8-K Ex 99.1 |
| Q1 2026 | revenue $600m to $625m, actual $608.1m; adjusted EBITDA $35m to $55m, actual $44.3m | 8-K Ex 99.1 |
| Q2 2026 | revenue $680m to $700m, actual $753.2m; adjusted EBITDA $35m to $55m, actual $60.3m | 8-K Ex 99.1 |
| Q3 2026 | revenue $880m to $900m, actual $890.4m; adjusted EBITDA $75m to $95m, actual $82.4m | 8-K Ex 99.1 |
| Q4 2026 | revenue $875m to $895m, +42% to +45% on Q4 2025 ($617.8m); adjusted EBITDA $70m to $90m (8% to 10% margin) | 8-K Ex 99.1, 9 Nov 2026 |
| 2030 targets | at least $6.5bn revenue and $1.3bn adjusted EBITDA | Q4 2025 letter; reiterated in 2026 releases |
| Speaker | Date and source | Statement |
|---|---|---|
| Andrew Dudum, CEO | 9 Nov 2026, 8-K Ex 99.1 Q3 2026 | “In healthcare, whoever owns the customer relationship wins” |
| Yemi Okupe, CFO | 9 Nov 2026, 8-K Ex 99.1 Q3 2026 | “Revenue grew 49% year‑over‑year, our second consecutive quarter of acceleration” |
| Andrew Dudum, CEO | 11 May 2026, 8-K Ex 99.1 Q1 2026 | “2026 is a defining year for Hims & Hers.” |
| Item | Disclosure |
|---|---|
| 10-Q Q3 2026, gross margin | 57% against 74%; product and packaging costs +176%, shipping +64%; management expects gross margin below prior periods in the near term. |
| 10-Q Q3 2026, weight loss | March 2026 shift to branded GLP‑1 (Novo Nordisk products) with compounded GLP‑1 on a limited scale; shorter shipping cadences lower gross margin and shift revenue timing. |
| 10-Q Q3 2026, liquidity | Working capital deficit $114.8m driven by $478.6m of current Eucalyptus deferred consideration, which can be settled mostly in shares (cap 19.9%); revolver $161.0m available; receivables facility $400m uncommitted; contractual obligations $1.08bn, $607.0m within 12 months. |
| 10-Q Q3 2026, adjusted EBITDA | Definition revised in Q2 2025 (payroll tax on stock compensation), Q1 2026 (restructuring) and Q3 2026 (FX gains and losses, not recast). |
| 10-Q Q3 2026, legal | FTC, Utah and Los Angeles County lawsuit of 29 Jul 2026 (FTC Act Section 5, ROSCA), about $60m accrued, motion to dismiss hearing 14 Jan 2027; SEC Division of Enforcement investigation since Feb 2026 on compounded semaglutide disclosures; HHS referral to the DOJ in Feb 2026; Velanki securities class action filed 1 Sep 2026. |
| 10-Q Q3 2026, exhibits | Ex 10.2: revolving credit facility Amendment No. 5 (25 Aug 2026) on guarantor exclusions; Ex 10.3: Amending Deed No. 2 to the Eucalyptus Securities Sale Deed (29 Sep 2026) on deferred payment timing. |
| 10-K FY2025, competition | Hims & Hers believes no direct competitor offers its full suite; it competes with traditional providers, pharmacies, retailers, niche telehealth firms, compounders and drug makers selling direct to consumers. |
| 10-K FY2025, controls | Controls effective at 31 Dec 2025; Zava excluded from the assessment (under 3% of assets, under 5% of revenue). |
| 10-K FY2025, investment | Over $300m of capital spending over three years and over 1 million square feet of US facilities (Q4 2025 letter); FY2025 capex $242.6m. |
| Company | Revenue TTM ($bn) | Revenue growth (%) | Gross margin (%) | Operating margin (%) | Net margin (%) | FCF margin (%) | ROE (%) | Net cash ($bn) | Market value ($bn) | EV/Sales (x) | P/E TTM (x) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HIMS | 2.9 | 48.6 | 63.8 | (8.1) | (6.7) | 0.3 | (53.7) | (0.7) | 4 | 1.8 | n/a |
| TDOC | n/a | (3.4) | n/a | (4.6) | (4.5) | n/a | n/a | n/a | 2 | n/a | n/a |
| GDRX | n/a | 9.7 | n/a | 17.3 | 8.8 | n/a | n/a | (0.2) | 1 | n/a | n/a |
| LFMD | n/a | (3.5) | 88.8 | (15.1) | (15.0) | n/a | n/a | n/a | 0 | n/a | n/a |
| WW | n/a | (11.2) | 71.1 | 23.9 | 9.9 | n/a | n/a | (0.3) | 0 | n/a | n/a |
| LLY | 86.5 | 38.6 | 83.6 | 40.3 | 31.9 | 22.7 | 82.6 | (44.6) | 1,347 | 16.1 | 46.5 |
| NVO | n/a | 4.0 | 77.0 | 29.1 | 21.1 | 36.0 | n/a | n/a | n/a | n/a | n/a |
| Date | Items | Event |
|---|---|---|
| 9 Nov 2026 | 5.02 | Board appointment (event 4 Nov 2026): board expanded from nine to ten; Dr. Andrew Huberman appointed a non independent director with no committee seat; $50,000 cash retainer and $250,000 annual equity award, prorated. Related paid agreements of 5 Nov 2026: two year advisory agreement at $3.5m a year in cash plus up to $1.0m a year for short form videos; podcast marketing agreement of up to three years with Scicomm Media, which he co founded and co owns, at $5.0m a year, his interest about $2.1m a year. No exhibit; agreements to be filed with the FY2026 10-K. |
| 9 Nov 2026 | 2.02, 8.01, 9.01 | Q3 2026 results (Ex 99.1): revenue $890.4m, +49%; gross margin 57%; net loss $33.0m; adjusted EBITDA $82.4m; subscribers 2.788m. Q4 2026 guidance revenue $875m to $895m, adjusted EBITDA $70m to $90m; FY2026 revenue $3.13bn to $3.15bn, adjusted EBITDA $257m to $277m. |
| 7 Oct 2026 | 5.02 | Jonathan Franklin, former VP Corporate Controller of Rivian, joined as chief accounting officer on 5 Oct 2026 and was appointed principal accounting officer effective 9 Oct 2026: salary $425,000, $150,000 signing bonus, $3.0m RSU grant, 50% target bonus. |
| 10 Aug 2026 | 2.02, 9.01 | Q2 2026 results: revenue $753.2m, +38%; net loss $86.3m; adjusted EBITDA $60.3m; subscribers 2.891m. FY2026 revenue guidance raised to $3.1bn to $3.3bn; adjusted EBITDA lowered to $275m to $325m. |
| 17 Jul 2026 | 5.02 | Chief Accounting Officer Irene Becklund to resign effective 9 Oct 2026; advisory agreement to 10 Jul 2027. No exhibit. |
| 1 Jul 2026 | 1.01, 2.03, 9.01 | Master Receivables Purchase Agreement with JPMorgan Chase (Ex 10.1): $400m limit, 364 day term, parent performance undertaking. Revolving credit facility Amendment No. 4 of 26 Jun 2026 (Ex 10.2) adds a $400m debt basket for it. |
| 15 Jun 2026 | 5.07 | Annual meeting of 11 Jun 2026: nine directors elected, KPMG ratified, advisory say on pay approved. No exhibit. |
| 2 Jun 2026 | 1.01, 2.03, 8.01, 9.01 | Revolving credit facility Amendment No. 3 of 29 May 2026 (Ex 10.1) to permit the Eucalyptus closing; release on completion of the Eucalyptus acquisition on 1 Jun 2026 (Ex 99.1), 850,000 customers served. |
| 21 May 2026 | 1.01, 2.03, 3.02, 9.01 | Issued $402.5m of 0% convertible senior notes due 1 Jun 2032 (indenture Ex 4.1); capped calls costing about $36.7m with HSBC, Barclays, BNP Paribas, Truist and Morgan Stanley (Ex 10.1, 10.2). |
| 19 May 2026 | 8.01, 9.01 | Announced and priced an upsized $350m convertible notes offering due 2032 plus a $52.5m option; conversion price about $29.53, 32.5% above the $22.29 close of 18 May 2026; cap price $50.15 (Ex 99.1, 99.2). |
| 11 May 2026 | 2.02, 9.01 | Q1 2026 results: revenue $608.1m, +4%; net loss $92.1m; adjusted EBITDA $44.3m; subscribers 2.584m. FY2026 guidance revenue $2.8bn to $3.0bn, adjusted EBITDA $275m to $350m. Move to an annual shareholder letter. |
| 11 Mar 2026 | 7.01, 9.01 | Release of 9 Mar 2026: US weight loss shifts to FDA approved GLP‑1s under an agreement with Novo Nordisk to offer Ozempic and Wegovy pills and injections; compounded GLP‑1 no longer advertised and offered on a limited scale; Novo Nordisk dismissed its patent suit without prejudice. |
| 23 Feb 2026 | 2.02, 9.01 | Q4 and FY2025 results (Ex 99.1 release, Ex 99.2 letter): FY2025 revenue $2.35bn, +59%; net income $128.4m; adjusted EBITDA $318.0m. FY2026 guidance revenue $2.7bn to $2.9bn, adjusted EBITDA $300m to $375m; 2030 targets of at least $6.5bn revenue and $1.3bn adjusted EBITDA. |
| 19 Feb 2026 | 1.01, 3.02, 7.01, 9.01 | Securities Sale Deed to acquire Eucalyptus (Ex 2.1) for up to about $1.15bn: about $240m upfront, about $710m deferred over 18 months, up to about $200m of earn outs; up to about 60% of deferred and earn out payments may be paid in Class A shares (Ex 99.1). |
| 17 Nov 2025 | 8.01 | Share repurchase program of up to $250m through 11 Nov 2028 (approved 13 Nov 2025); 1,334,572 shares bought for $55.5m from 1 Oct to 7 Nov 2025 completed the $100m 2024 program. |
| Contract | Terms |
|---|---|
| 0% convertible senior notes due 2030 | $1.00bn issued May 2025, maturity 15 May 2030, conversion price $70.67; capped calls $47.8m; redeemable from 19 May 2028; carrying $977.2m, fair value $858.8m at 30 Sep 2026. |
| 0% convertible senior notes due 2032 | $402.5m issued 21 May 2026, maturity 1 Jun 2032, conversion price $29.53 (32.5% premium); capped calls $36.7m with cap $50.15; net proceeds $389.5m; redeemable from 6 Jun 2029; fair value $503.8m at 30 Sep 2026. |
| Revolving credit and guaranty agreement (JPMorgan, agent) | $175m to 18 Feb 2028, accordion $125m; term SOFR plus 0.10% plus 1.50% to 2.00%; total leverage at most 3.50x, interest coverage at least 3.00x; undrawn, $14.0m letters of credit, $161.0m available at 30 Sep 2026. |
| Revolver amendments | No. 1 (25 Jun 2025); No. 2 (7 May 2026): investments added to cash equivalents in the leverage ratio; No. 3 (29 May 2026): Eucalyptus closing, joinder of material foreign subsidiaries; No. 4 (26 Jun 2026): $400m basket for the receivables facility; No. 5 (25 Aug 2026, 10-Q Ex 10.2): subsidiaries on Schedule 1.1(b) excluded from guarantees, each until its own four quarter gross revenue reaches 5% of consolidated gross revenue. |
| Master Receivables Purchase Agreement | JPMorgan Chase as purchaser, signed 1 Jul 2026, $400m limit, 364 days, extendable, uncommitted; sellers XeCare and Apostrophe Pharmacy; true sale. Q3 2026: $434.5m of receivables sold for $433.3m, in operating cash flow. |
| Eucalyptus Securities Sale Deed and amendments | Purchase price $968.5m: $225.0m upfront, $683.9m deferred in six instalments over 18 months from 1 Jun 2026, earn out fair value $59.6m (maximum $96.6m); $130.3m paid in 9M 2026; most deferred and earn out amounts may be paid in Class A shares, capped at 19.9%. Amending Deed No. 2 of 29 Sep 2026 (10-Q Ex 10.3) changes payment timing in clause 4.2(b). |
| Novo Nordisk collaboration | Agreement announced 9 Mar 2026 to offer Ozempic and Wegovy pills and injections on the platform; financial terms not filed. |
| Huberman agreements (5 Nov 2026) | Advisory agreement $3.5m a year for two years plus up to $1.0m a year for videos; podcast marketing agreement with Scicomm Media $5.0m a year for up to three years; to be filed with the FY2026 10-K. |
| Proposal | For (bn votes) | Against (bn votes) | Abstain (bn votes) | For as % of votes cast | Result |
|---|---|---|---|---|---|
| Election of Andrew Dudum | 1.505 | 0.013 | none (plurality vote) | 99.1 | elected |
| Election of Kofi Amoo‑Gottfried | 1.517 | 0.001 | none (plurality vote) | 100.0 | elected |
| Election of Deborah Autor | 1.516 | 0.002 | none (plurality vote) | 99.9 | elected |
| Election of Delos Cosgrove | 1.517 | 0.001 | none (plurality vote) | 99.9 | elected |
| Election of Anja Manuel | 1.517 | 0.001 | none (plurality vote) | 99.9 | elected |
| Election of Christopher Payne | 1.509 | 0.009 | none (plurality vote) | 99.4 | elected |
| Election of Andrea Perez | 1.517 | 0.001 | none (plurality vote) | 99.9 | elected |
| Election of Kare Schultz | 1.517 | 0.001 | none (plurality vote) | 99.9 | elected |
| Election of David Wells | 1.502 | 0.016 | none (plurality vote) | 98.9 | elected |
| Ratify KPMG for FY2026 | 1.591 | 0.001 | 0.000 | 100.0 | approved |
| Advisory say on pay | 1.506 | 0.011 | 0.000 | 99.3 | approved |
| Holder | Class A (m) | Class V (m) | Share of class or votes | Source |
|---|---|---|---|---|
| Andrew Dudum (CEO), incl. trusts | 15.39 | 8.38 | 87.73% of votes | 2026 proxy |
| BlackRock | 23.05 | 10.35% of Class A; 1.36% of votes | 2026 proxy | |
| Capital World Investors | 14.32 | 6.43% of Class A | 2026 proxy | |
| Directors and executive officers as a group | 18.79 | 8.38 | 8.44% of Class A; 87.93% of votes | 2026 proxy |
| Risk | Disclosure and change |
|---|---|
| Compounding and the branded GLP‑1 shift (reworded in FY2025 10-K and Q1 2026 10-Q) | End of the semaglutide shortage on 21 Feb 2025 limited 503B compounding; the Feb 2026 FDA statement named Hims & Hers. Restructuring $41.9m in 9M 2026; gross margin 57.2% in Q3 2026. |
| Government actions and public statements (added, FY2025 10-K) | FDA warning letters (Sep and Dec 2025), Feb 2026 FDA statement and HHS referral to the DOJ, SEC investigation since Feb 2026 and the FTC lawsuit of 29 Jul 2026 with about $60m accrued. |
| Eucalyptus acquisition and funding (added, FY2025 10-K) | Deferred and earn out payments could strain cash or dilute holders if settled in shares; deferred payable $563.1m at 30 Sep 2026, earn outs $170.7m in total. |
| Indebtedness and convertible notes (added, Q2 2026 10-Q) | $1.40bn of convertible principal; conversion prices $70.67 and $29.53 against a $19.13 close. |
| AI investments (added, Q2 2026 10-Q) | Investment in AI may not deliver the expected benefits; the Q3 2026 release describes an AI native experience being rolled out. |
| Testosterone replacement therapy (added, Q3 2026 10-Q) | The 2026 launch includes Schedule III controlled substances, which require DEA registration and state compliance. |
| Influencers and promotion outside the US (reworded) | UK, EU and Canadian rules prohibit promotion of prescription only medicines to the public, incl. influencer promotion of weight loss treatments; Rest of the World was 26.2% of Q3 2026 revenue. |
| Dual class structure | CEO Andrew Dudum controls 87.7% of voting power through Class V shares with 175 votes each. |
| Measure | 10-K FY2024 | 10-K FY2025 |
|---|---|---|
| Risk factors (count) | 63 | 71 |
| Words in Item 1A | 28,690 | 33,360 |
| Change | Risk factor | What changed |
|---|---|---|
| Added | Eucalyptus deal subject to conditions, may not close | New section on the 19 Feb 2026 deal: closing depends on regulatory approvals and other conditions under New South Wales law. |
| Added | Funding plan for Eucalyptus exposed to weaker results | Upfront, deferred (18 months) and earn out payments could strain cash if operating results or capital markets weaken; share settlement could dilute holders. |
| Added | Expected benefits of Eucalyptus may not be realized | Integration of operations in Australia, UK, Germany, Canada and Japan may not deliver anticipated growth. |
| Added | FDA warning letters on specimen collection kits | FDA has issued warning letters on at home specimen collection kits; similar action against kits used for the Labs offering could disrupt it. |
| Added | FDA regulation of laboratory developed tests | New exposure from the lab testing facility and Labs offering launched in 2025 to LDT rules in the US and diagnostic rules abroad. |
| Added | Sample collection kits as prescription devices need state licenses | Kits could be deemed prescription devices requiring state distribution licenses, 510(k) or other FDA authorization. |
| Added | Perceptions of compounded drug safety and quality | Negative public perception of compounded drugs, including GLP‑1s, could reduce demand and harm the business. |
| Added | Actions and public statements by US officials and agencies | Cites Sep 2025 FDA warning letters on compounded semaglutide website claims and the Feb 2026 HHS statement referring the company to the DOJ. |
| Reworded | Expanding or maintaining scope of offerings | Replaces the 2024 shortage narrative with the 21 Feb 2025 end of the semaglutide shortage, limits on 503B compounding and the Feb 2026 FDA statement naming the company. |
| Reworded | Pharmacy business adds healthcare regulation | Adds UK GPhC and MHRA rules and Canadian provincial pharmacy regulation after Zava and Medici; drops text on not owning XeCare and Apostrophe Pharmacy (now wholly owned). |
| Reworded | Failure to comply with healthcare laws | Grows from 1,779 to 2,229 words: Dec 2025 warning letter to the 503B Outsourcing Facility, Feb 2026 FDA statement and HHS DOJ referral, peptide facility (Feb 2025), Zava and Medici foreign regimes. |
| Reworded | Fines for promoting unapproved uses or drugs | Extends to UK, EU and Canada regulators and their ban on promoting prescription only medicines; notes prior FDA warning letters on promotion of compounded products. |
| Reworded | Public scrutiny of privacy and security | Grows from 626 to 992 words with EU GDPR, UK GDPR transfer rules and Canadian privacy and AI rules. |
| Reworded | Use of social media and influencers | Heading drops 'celebrity'; adds UK, EU and Canada prohibition on influencer promotion of prescription medicines, especially weight loss treatments. |
| Reworded | International expansion important for growth | Heading drops 'long‑term'; lists Zava (Jul 2025), Medici (Nov 2025) and the Feb 2026 Eucalyptus agreement. |
| Reworded | Anti‑kickback, self referral and false claims laws | Adds whistleblower provisions of the False Claims Act and clarifies that the company does not accept third party payor payments in the US. |
| Reworded | Claims of infringing others' intellectual property | Heading now says the company 'is' subject to such claims; cites the 9 Feb 2026 Novo Nordisk patent suit over compounded semaglutide. |
| Reworded | Legal and regulatory proceedings and inquiries | Heading adds 'regulatory' proceedings and inquiries; text adds securities class action and derivative suits and the FTC information requests. |
| Reworded | Estimates in main accounting policies | Adds valuation of acquired assets, intangible useful lives, deferred tax assets, inventory and refund reserve estimates. |
| Reworded | Class A stock price volatile | Heading changed from 'may be volatile' to 'has been and may continue to be volatile'. |
| Filing | Change disclosed |
|---|---|
| 10-Q Q1 2026 filed 11 May 2026 | Full Item 1A restated; 71 factors, 4 materially reworded: March 2026 shift to branded GLP‑1 with limited compounding, legal proceedings text adds FTC findings (Apr 2026), settlement talks and Feb 2026 SEC Enforcement investigation, cybersecurity factor adds the Feb 2026 social engineering incident, profitability factor cites Q1 2026 net loss of $92.1m. |
| 10-Q Q2 2026 filed 10 Aug 2026 | Groups regrouped into four; 72 factors. Added: AI investments may not deliver benefits; indebtedness and liabilities ($1.4bn convertible principal at 30 Jun 2026); ability to fund convertible repurchase or conversion. Removed: two Eucalyptus closing and benefit factors after the 1 Jun 2026 close. Privacy factor rewritten (768 to 1,432 words); legal factor names the FTC investigation under the FTC Act and ROSCA. |
| 10-Q Q3 2026 filed 9 Nov 2026 | 73 factors. Added: testosterone replacement therapy launched in 2026 includes Schedule III controlled substances (DEA registration, state rules). Reworded: supply chain factor drops branded GLP‑1 supply constraint text; security factor adds AI enabled attacks; Russia and Ukraine references removed from macro factors. |
| Factor | Current value | Best case requires | Evidence in filings and calls |
|---|---|---|---|
| US revenue after the branded GLP‑1 shift | $657.1m in Q3 2026, +21% | US growth of 15% to 20% a year | US growth (8%) in Q1, +16% in Q2, +21% in Q3 2026 (8-K Ex 99.1) |
| Gross margin | 57.2% in Q3 2026 | recovery to about 60% to 65% | 73.8% in Q3 2025; 10-Q expects gross margin below prior periods near term |
| International scale | Rest of the World $233.3m, 26.2% of revenue | above $1bn a year with positive adjusted EBITDA | Q3 2025 letter: international markets above $1bn of revenue potential |
| Subscriber growth | 2.788m, +13%, about 103,000 fewer than Q2 2026 | growth back above 15% a year | 2.891m at Q2 2026 (8-K Ex 99.1) |
| Legal and regulatory outcome | about $60m FTC accrual; SEC investigation; DOJ referral; securities suits | resolution near the accrued amount without business restrictions | 10-Q legal proceedings note |
| Dilution and capital | 234.41m shares; $1.40bn convertibles; $563.1m Eucalyptus deferred | deferred payments made in cash from operating cash flow | share settlement option capped at 19.9% (10-Q) |
| Measure | Worst case | Base case | Best case |
|---|---|---|---|
| Revenue CAGR, 3 years (%) | 4.0 | 14.0 | 22.0 |
| Revenue, TTM Q3 2029 ($bn) | 3.2 | 4.3 | 5.2 |
| Exit EV/Sales (x) | 0.8 | 1.2 | 3.0 |
| Implied price ($) | 7 | 17 | 57 |
| Change against $19.13 (%) | (62) | (11) | 200 |
| Implied annual return (%) | (27.5) | (3.9) | 44.3 |
| Description | Low US growth; legal costs; share settled payments | Mid teens growth from the FY2026 guidance midpoint | International above $1bn; new specialties scale; gross margin near 60% |
| Revenue CAGR \ EV/Sales | 1x | 2x | 3x | 4x |
|---|---|---|---|---|
| 0% | $8 | $19 | $30 | $41 |
| 4% | $10 | $22 | $35 | $47 |
| 9% | $12 | $26 | $40 | $55 |
| 14% | $14 | $30 | $46 | $63 |
| 18% | $15 | $34 | $52 | $70 |
| 22% | $17 | $37 | $57 | $78 |
This analysis is for information only and is not financial advice. It is derived from public SEC filings retrieved via sec-api.io and is not a publication of the U.S. Securities and Exchange Commission. Scenario values are model outputs under stated assumptions and are not forecasts. Data as of 10 November 2026.
All company and peer figures are read from SEC filings retrieved through the sec-api.io MCP server. Share prices are closing prices.
| Form | Period | Filed | Accession number |
|---|---|---|---|
| 10-Q | Q3 2026 | 9 Nov 2026 | 0001773751-26-000246 |
| 8-K Ex 99.1 | Q3 2026 | 9 Nov 2026 | 0001773751-26-000242 |
| 8-K Item 5.02 | 4 Nov 2026 | 9 Nov 2026 | 0001773751-26-000245 |
| 10-Q | Q2 2026 | 10 Aug 2026 | 0001773751-26-000163 |
| 10-Q | Q1 2026 | 11 May 2026 | 0001773751-26-000076 |
| 10-K | FY2025 | 23 Feb 2026 | 0001773751-26-000022 |
| 10-K | FY2023 | 26 Feb 2024 | 0001773751-24-000025 |
| 10-K | FY2022 | 27 Feb 2023 | 0001773751-23-000029 |
| 8-K Ex 99.1/99.2 | Q4 2025 | 23 Feb 2026 | 0001773751-26-000019 |
| DEF 14A | 2026 | 28 Apr 2026 | 0001773751-26-000060 |
| Company | Form | Filed | Accession number |
|---|---|---|---|
| Hims & Hers | 10-K FY2024 | 24 Feb 2025 | 0001773751-25-000062 |
| Hims & Hers | 8-K Ex 99.2, Q4 2024 letter | 24 Feb 2025 | 0001773751-25-000059 |
| Hims & Hers | 8-K (Items 8.01) | 17 Nov 2025 | 0001773751-25-000362 |
| Hims & Hers | 8-K (Items 1.01, 3.02, 7.01, 9.01) | 19 Feb 2026 | 0001773751-26-000010 |
| Hims & Hers | 8-K (Items 7.01, 9.01) | 11 Mar 2026 | 0001773751-26-000033 |
| Hims & Hers | 8-K (Items 2.02, 9.01) | 11 May 2026 | 0001773751-26-000074 |
| Hims & Hers | 8-K (Items 8.01, 9.01) | 19 May 2026 | 0001193125-26-229749 |
| Hims & Hers | 8-K (Items 1.01, 2.03, 3.02, 9.01) | 21 May 2026 | 0001193125-26-234847 |
| Hims & Hers | 8-K (Items 1.01, 2.03, 8.01, 9.01) | 2 Jun 2026 | 0001773751-26-000091 |
| Hims & Hers | 8-K (Items 5.07) | 15 Jun 2026 | 0001773751-26-000096 |
| Hims & Hers | 8-K (Items 1.01, 2.03, 9.01) | 1 Jul 2026 | 0001773751-26-000146 |
| Hims & Hers | 8-K (Items 5.02) | 17 Jul 2026 | 0001773751-26-000149 |
| Hims & Hers | 8-K (Items 2.02, 9.01) | 10 Aug 2026 | 0001773751-26-000161 |
| Hims & Hers | 8-K (Items 5.02) | 7 Oct 2026 | 0001773751-26-000220 |
| Eli Lilly | 10-Q Q3 2026 | 29 Oct 2026 | 0000059478-26-000108 |
| Eli Lilly | 8-K | 29 Oct 2026 | 0000059478-26-000104 |
| GoodRx | 8-K Item 4.02 | 2 Nov 2026 | 0001809519-26-000184 |
| LifeMD | 10-Q | 5 Aug 2026 | 0001493152-26-036200 |
| Novo Nordisk | 6-K | 4 Nov 2026 | 0001628280-26-069805 |
| Teladoc Health | 10-Q | 29 Oct 2026 | 0001477449-26-000052 |
| WW International | 10-Q | 5 Nov 2026 | 0001193125-26-448563 |
| Filed | Exhibit | Document | Content |
|---|---|---|---|
| 19 Feb 2026 | EX-2.1 | Securities Sale Deed for Eucalyptus (EUC Management Pty Ltd) | Purchaser Horizon BidCo Pty Ltd; guarantor Hims, Inc.; deed dated 19 Feb 2026 (summarised from 8-K Item 1.01); Consideration up to about $1.15bn: about $240m upfront, about $710m deferred, up to about $200m earn outs |
| 19 Feb 2026 | EX-99.1 | Press release: agreement to acquire Eucalyptus | Eucalyptus operates in Australia, UK, Germany, Japan and Canada; brands Juniper and Pilot; more than 775,000 customers; Annual revenue run rate above $450m (non GAAP, January 2026 gross fulfilled billings annualised); triple digit ARR growth each quarter of 2025 |
| 23 Feb 2026 | EX-99.1 | Q4 and FY2025 results press release | Q4 2025 revenue $617.8m (+28%); FY2025 revenue $2.35bn (+59%); FY2025 net income $128.4m; Adj. EBITDA $318.0m vs $176.9m; FCF $57.4m vs $198.3m |
| 23 Feb 2026 | EX-99.2 | Q4 2025 shareholder letter | Weight Loss, Men's Dermatology, Sexual Health and Women's Dermatology each above $100m annual revenue; Hers approaching $1bn; Hims revenue grew more than 30% and Hers more than 100% in 2025; majority of 2025 revenue from non GLP‑1 offerings |
| 11 Mar 2026 | EX-99.1 | Strategic shift for US weight loss; Novo Nordisk collaboration (release dated 9 Mar 2026) | US weight loss to focus on FDA approved GLP‑1s; compounded semaglutide offered on a limited scale when clinically necessary; No further advertising of compounded GLP‑1 offerings |
| 11 May 2026 | EX-99.1 | Q1 2026 results press release | Revenue $608.1m (+4%); US $529.9m (-8%); Rest of World $78.2m (+969%); Gross margin 65% vs 73%; net loss $92.1m; Adj. EBITDA $44.3m vs $91.1m |
| 19 May 2026 | EX-99.1 | Press release: proposed $300m convertible notes offering due 2032 | Proposed private offering of $300m convertible senior notes due 2032 under Rule 144A; Proceeds for international expansion including Eucalyptus, technology and capped calls |
| 19 May 2026 | EX-99.2 | Press release: pricing of upsized $350m 0% convertible notes due 2032 | Upsized to $350m from $300m, plus $52.5m option; 0% coupon, maturity 1 Jun 2032; Conversion price about $29.53, 32.5% premium to $22.29 close on 18 May 2026 |
| 21 May 2026 | EX-4.1 | Indenture for 0% Convertible Senior Notes due 2032 (US Bank Trust Company, trustee) | $402.5m principal issued 21 May 2026 (option exercised in full); Initial conversion rate 33.8590 shares per $1,000 (about $29.53) |
| 21 May 2026 | EX-10.1 / EX-10.2 | Forms of base and additional capped call confirmations | Counterparties HSBC, Barclays, BNP Paribas, Truist and Morgan Stanley; Cap price about $50.15 (125% premium to 18 May 2026 price) |
| 2 Jun 2026 | EX-10.1 | Amendment No. 3 to Revolving Credit and Guaranty Agreement (29 May 2026) | Facilitates Eucalyptus closing with grace period for covenant and representation compliance; Adds joinder obligations for material foreign subsidiaries |
| 2 Jun 2026 | EX-99.1 | Press release: completion of Eucalyptus acquisition | Closed (1 Jun 2026); presence across US, UK, Australia, Canada; growing in France, Germany, Ireland, Spain, Japan; Eucalyptus has served more than 850,000 customers (as of May 2026) |
| 1 Jul 2026 | EX-10.1 | Master Receivables Purchase Agreement with JPMorgan Chase (1 Jul 2026) | Sellers XeCare LLC and Apostrophe Pharmacy LLC; $400m facility limit; purchaser may decline any offer; Initial term 364 days, extendable by agreement |
| 1 Jul 2026 | EX-10.2 | Amendment No. 4 to Revolving Credit Agreement (26 Jun 2026) | Permits the RPA and performance undertaking; New permitted debt basket of up to $400m for the RPA |
| 10 Aug 2026 | EX-99.1 | Q2 2026 results press release | Revenue $753.2m (+38%); US $621.8m (+16%); Rest of World $131.4m (+1,641%); Gross margin 64% vs 76%; net loss $86.3m; Adj. EBITDA $60.3m vs $82.2m |
| 9 Nov 2026 | EX-99.1 | Q3 2026 results press release | Revenue $890.4m (+49%); US $657.1m (+21%); Rest of World $233.3m (+321%); Gross margin 57% vs 74%; net loss $33.0m vs net income $15.8m |
| 9 Nov 2026 | EX-10.2 (10-Q) | Amendment No. 5 to Revolving Credit and Guaranty Agreement (25 Aug 2026) | Adds clause (e) to Excluded Subsidiary: subsidiaries on Schedule 1.1(b) excluded from guarantee requirements even if Material Foreign Subsidiary; Exclusion ends once a listed subsidiary's trailing four quarter gross revenue reaches 5% of consolidated gross revenue |
| 9 Nov 2026 | EX-10.3 (10-Q) | Amending Deed No.2 to Eucalyptus Securities Sale Deed (29 Sep 2026) | Parties H&H Australia Intermediate Holdings and Shareholder Representative Services LLC; Deletes 'the first Business Day of the calendar month immediately following' from clause 4.2(b), changing payment timing |
November 11, 2026·49 min read
November 11, 2026·41 min read